This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LeadingBiotech: Cancer Advance
March 5, 2020
Koch Institute for Integrative Cancer Research at MITCambridge, MA

Lori Wirth, MD
The Elizabeth & Michael Ruane Endowed Chair of Medical Oncology; Medical Director of Massachusetts General Hospital Center for Head & Neck Cancers; at Associate Professor in Medicine, Harvard Medical School


Lori J. Wirth, MD is the Elizabeth and Michael Ruane Endowed Chair of Medical Oncology, Medical Director of Massachusetts General Hospital’s Center for Head and Neck Cancers, and Associate Professor in Medicine at Harvard Medical School. Dr. Wirth received her BA from Brown University and MD from Columbia University’s College of Physicians and Surgeons. She trained at New York Presbyterian Hospital and Dana-Farber/Harvard Cancer Center.

Dr. Wirth is an internationally recognized expert in advanced thyroid cancer and head and neck oncology, with expertise new therapies for head and neck and thyroid cancers. Her research focuses on clinical trials and leveraging translational data to maximize the impact of trial outcomes.

In addition to overseeing the Center for Head and Neck Cancers, Dr. Wirth co-directs Mass General/Mass Eye and Ear’s Advanced Thyroid Cancer Clinic. Dr. Wirth is Past Chairperson of the International Thyroid Oncology Group, and sits on a number of national and international oncology committees, including the National Comprehensive Cancer Network’s Thyroid Committee, the American Thyroid Association Differentiated Thyroid Cancer Guidelines Committee and the American Board of Internal Medicine’s Medical Oncology Exam Committee.

Agenda Sessions

  • The Perfect Pairing: Leveraging Combo Therapy for Oncology Drug Development